Most Read Articles
Stephen Padilla, 3 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
4 days ago
Socioeconomic status, along with other social determinants, appears to influence the long-term outcomes in Asian acute heart failure patients, according to a recent Japan study.
Pearl Toh, 6 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
Jairia Dela Cruz, 3 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.

Brodalumab treatment does not cause suicidality in patients with psoriasis

Stephen Padilla
04 Jan 2018

There is no causal relationship between suicidality and treatment with brodalumab, according to data from five clinical trials.

A total of 4,464 patients with psoriasis with 9,161.8 patient-years of brodalumab exposure were included in the analysis. Throughout the 52-week controlled phases, the brodalumab and ustekinumab groups showed comparable follow-up time‒adjusted incidence rates of suicidal ideation and behaviour (SIB) events (0.20 vs 0.60 per 100 patient-years). [J Am Acad Dermatol 2018;78:81–89.e5]

“Given the prevalence of SIB risk factors among individuals with psoriasis and at baseline in brodalumab clinical trials, it is not surprising that SIB events occurred in the brodalumab trials and that most patients with SIB events during the brodalumab trials had a history of predisposing risk factors,” researchers said. [Arch Dermatol 2010;146:891–895; J R Soc Med 2014;107:194–204; J Invest Dermatol 2015;135:984–991; J Int Med Res 2016;44:61–66]

Brodalumab showed a similar rate of SIB events with those observed with placebo or ustekinumab during the induction phase, and to that with ustekinumab during the first year of treatment. Psychiatric adverse events (AEs) were also similar in patients receiving brodalumab and in those receiving placebo over 12 weeks as well as in patients receiving ustekinumab over 12 and 52 weeks.

Four completed suicides occurred in the brodalumab group over a total of 9,161.8 patient-years. One of these was later decided as indeterminate. All patients presented with underlying psychiatric disorders or stressors.

“The rates of suicidal behaviour AEs or completed suicides did not increase over time in the brodalumab treatment group,” researchers noted. “These observations highlight the lack of evidence of a causal relationship between brodalumab and SIB.”

There were specific exclusion criteria for psychiatric disorders or substance abuse in most clinical trials of systemic drugs for moderate-to-severe psoriasis, but such criteria in the brodalumab studies were limited to more closely represent the general psoriasis patient population, allowing patients with SIB risk factors at baseline to participate, researchers said.

“Even with more restrictive exclusion criteria, SIB events have been reported in clinical trials of other agents used to treat psoriasis, including adalimumab, apremilast, certolizumab, ixekizumab, secukinumab, and ustekinumab,” researchers said. [J Drugs Dermatol 2016;15:1192–1196; Celgene Corporation, Summit, NJ; 2014; UCB, Inc, Smyrna, Georgia; 2016; Br J Dermatol 2013;168:844–854; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125521Orig1s000SumR.pdf; https://www.pharmamedtechbi.com//media/Supporting%20Documents/The%20Pink%20Sheet%20DAILY/2014/October/101614%20Novartis%20briefing%20docs.pdf]

Researchers analysed data from the following: a placebo-controlled, phase II clinical trial; the open-label, long-term extension of the phase II clinical trial; and three phase III, randomized double-blind, controlled clinical trials (AMAGINE-1, AMAGINE-2, and AMAGINE-3) and their open-label, long-term extensions of patients with moderate-to-severe psoriasis.

This study was limited by the absence of a comparator arm past week 52. Also, controlled study periods were not powered to detect differences in rare events such as suicide.

“Prescribers are encouraged to weigh the potential risks and benefits of brodalumab treatment in patients with a history of depression or SIB,” researchers said. “To assess a potential correlation between SIB and treatment of psoriasis, future studies should be adequately powered and patient SIB risk factors balanced at baseline.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 3 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
4 days ago
Socioeconomic status, along with other social determinants, appears to influence the long-term outcomes in Asian acute heart failure patients, according to a recent Japan study.
Pearl Toh, 6 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
Jairia Dela Cruz, 3 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.